Cadrenal Therapeutics Inc

This management proposal seeks shareholder approval to amend Cadrenal’s 2022 Successor Equity Incentive Plan to increase the share reserve by 323,542 shares to a total of 1,000,000 shares. Management argues the increase is necessary to sustain equity-based compensation as a core element of its talent retention and incentive strategy and to ensure sufficient runway for grants through mid‑2027, citing current low available shares (264,587 as of the record date) and recent evergreen increases. The amendment is also intended to satisfy Nasdaq requirements related to shareholder approval for equity compensation and to preserve the ability to grant options that can qualify as Incentive Stock Options under Section 422 of the Internal Revenue Code. The board frames the change as a preventative action to manage dilution and overhang by controlling annual grant levels while maintaining competitive compensation. Approval would permit the Compensation Committee to continue granting options, RSUs and other awards to executives, employees, directors and consultants without running short of authorized shares; if the amendment fails, the company states it will be constrained in granting awards and may need to seek additional approvals later. The company discloses that awards are discretionary and that the Compensation Committee reviews burn rate and overhang metrics, and that the board expects to issue grants to executives and directors if the increase is approved. Key governance limits are preserved in the plan, including shareholder consent required for repricing and limitations on annual ISO qualification; the amendment is a straightforward numeric increase and includes formal charter amendment language in Annex A. From an investor perspective, the proposal raises classic trade-offs: enabling management to grant equity to attract and retain talent versus additional potential dilution to existing holders; the company estimates the increase will be sufficient to cover issuances through June 2027, but provides limited long-term modeling of dilution scenarios.

This management proposal requests shareholder approval under Nasdaq Rule 5635(d) to permit exercisability of Series C-1 warrants issued in a July 1, 2026 private placement that would, upon full exercise, result in issuance of up to 960,000 shares (exceeding Nasdaq’s 20% threshold). The warrants were issued alongside pre-funded warrants and Series C-2 warrants in a negotiated institutional placement; only the Series C-1 warrants remain non-exercisable pending shareholder approval. The board states approval is required to comply with Nasdaq rules and to allow the company to receive potential cash proceeds from exercises and to avoid being contractually required to hold repeated special meetings every 90 days until approval is obtained. The Series C-1 Warrants carry a $3.00 exercise price, a five-year term measured from the later of stockholder approval or the effectiveness of a resale registration statement, and customary adjustment provisions for stock splits and similar events; the company may also, with holder consent, reduce exercise price subject to Nasdaq rules. Management has filed a Form S-3 registration statement and entered into registration rights to facilitate resale of shares underlying the warrants, which mitigates some liquidity and secondary-market concerns. Approval would be dilutive to existing shareholders and could create downward pressure on the stock if the Warrant Shares are sold into the market; the filing warns of these dilution and market-pressure risks. From a governance lens, the approval is a routine compliance step tied to Nasdaq mechanics rather than a strategic corporate action, but it will materially increase the potential share count and thereby affects capital structure and potential future control dynamics depending on exercise and resale behavior.

The management-sponsored adjournment proposal seeks authority to postpone or adjourn the annual meeting if there are insufficient votes to pass the Plan Amendment and/or Warrant Exercise proposals, enabling additional solicitation time. The board argues this is in stockholders’ interests because it avoids immediately losing the opportunity to obtain approvals necessary for equity-plan capacity and Nasdaq compliance tied to the private placement warrants, and it can reduce transaction costs compared with holding multiple full meetings. If approved, proxies solicited by the board may be used to adjourn the meeting to a later date or to omit immediate votes on the contested proposals while further solicitations occur. The proposal therefore functions as a tactical governance tool in the event of a narrow vote outcome and is commonly used in contested or close-vote situations to give management time to canvass and secure requisite support. Potential risks to investors include additional delay and the perception of management leveraging adjournment to change outcomes, which may be viewed critically by some investors; however, the company discloses that broker non-votes and abstentions have specified impacts on these non-routine proposals. The practical effect, if used, would be to preserve the company’s ability to attempt to obtain the approvals needed for compensation and financing mechanics rather than fail and potentially face recurring special meeting requirements tied to the warrant agreements.